Piper Sandler initiates coverage on Bio-Techne with Neutral rating
Piper Sandler analyst David Westenberg has initiated coverage on Bio-Techne with a Neutral rating and announced a price target of $65.
*this image is generated using AI for illustrative purposes only.
Piper Sandler analyst David Westenberg has initiated coverage on Bio-Techne with a Neutral rating and announced a price target of $65. This rating provides a benchmark for investors evaluating the stock's potential performance relative to the firm's projections.
The coverage initiation by Piper Sandler offers a new perspective on Bio-Techne's market position. The Neutral rating suggests that the stock is expected to perform in line with the broader market or industry averages over the specified period.
Key Details
| Metric | Value |
|---|---|
| Rating | Neutral |
| Price Target | $65 |
| Coverage Initiated By | Piper Sandler |
| Analyst | David Westenberg |
What specific factors could drive Bio-Techne's stock above the $65 price target?
How might Bio-Techne's upcoming product launches influence future analyst ratings?
What are the potential risks that could lead to a downgrade from the Neutral rating?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
